Australia Stock Exchange release from CLINUVEL PHARMAC : CLINUVEL Study to Evaluate SCENESSE as Vitiligo Monotherapy
19/12/2021 22:25
Australia Stock Exchange release from CLINUVEL PHARMAC CUV.AX : CLINUVEL Study to Evaluate SCENESSE as Vitiligo Monotherapy
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist